Tradestie Institutional Equity Comparison Engine

RAPT vs MNKD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RAPT Overall Edge

RAPT Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to RAPT Therapeutics, Inc. Common Stock (RAPT) driven by superior Growth & Margin, Momentum & Technical while MNKD counters with relative strength in Valuation, Options & Structure. Fundamentally, RAPT trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus MNKD at 26.2x Forward P/E and -3.4% operating margin (+24.0% YoY). In options structure, RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against MNKD sits in CONSOLIDATION (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNKD
RAPT N/M vs MNKD 26.2x Fwd P/E
Growth & Margin Winner RAPT
Op Margin 0.0% vs -3.4% ยท YoY -100.0% vs +24.0%
Momentum & Technical Winner RAPT
1Y +480.2% vs -22.2% ยท 52W Pos 100% vs 40%
Options & Structure Winner MNKD
UNCLASSIFIED (<1st %ile IV) vs CONSOLIDATION (7th %ile IV)
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
1M Return +0.68%
1Y Return +480.2%
Forward P/E N/M
Unified AI Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
MNKD NASDAQ
Mannkind Corporation
Pharmaceutical Preparations
$3.94
-4.48% 1D
Market Cap $1.3B
1M Return +29.77%
1Y Return -22.19%
Forward P/E 26.2x
Unified AI Score
38.4 / 100 SELL
Tech 8.0 Fund 38.0 Flow 72.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RAPT +480.2% MNKD -22.19% Spread: +141.97 pp (RAPT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RAPT TTM Op. Margin: 0.0% MNKD TTM Op. Margin: -3.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs MNKD. Trailing 12-month operating profitability (RAPT 0.0% vs MNKD -3.4%) and valuation multiples (RAPT N/M vs MNKD 26.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RAPT (6) vs MNKD (4)
Institutional Metric RAPT MNKD Criterion Row Winner
Market Capitalization Scale $1.7B $1.3B Larger Scale RAPT
Trailing P/E Ratio Valuation N/M 32.3x Lower Multiple MNKD
Forward P/E Ratio Valuation N/M 26.2x Lower Multiple MNKD
Revenue Growth (YoY) Growth -100.0% +24.0% Higher Growth MNKD
Operating Margin (TTM) Profitability 0.0% -3.4% Higher Margin RAPT
Net Profit Margin Profitability 0.0% -18.1% Higher Margin RAPT
Return on Equity (ROE) Capital Efficiency -85.4% 0.0% Higher ROE MNKD
52-Week Range Position Momentum 100% ($1โ€“$58) 40% ($2โ€“$7) Stronger Trend RAPT
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 2% Vol 1.30ฮฒ ยท 50% Vol Lower Realized Risk RAPT
Unified Institutional Score Composite Signal 52.4 / 100 (HOLD) 38.4 / 100 (SELL) Higher Composite RAPT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RAPT vs MNKD Buy Guide
RAPT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live RAPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNKD CONSOLIDATION
95d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live MNKD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RAPT nor MNKD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.